1. Antibody to the Human T-Lymphotropic Virus Type 1 (HTLV-1) Envelope Protein Gp46 in Patients Co-infected with HCV and HTLV-1
- Author
-
Norihiro Furusyo, Masayuki Murata, Yasuko Sagara, Jun Hayashi, Hiroaki Takeoka, Kazuhiro Toyoda, and Seizaburo Kashiwagi
- Subjects
Adult ,Male ,Cirrhosis ,Hepacivirus ,Hepatitis C virus ,Retroviridae Proteins, Oncogenic ,Enzyme-Linked Immunosorbent Assay ,Chronic liver disease ,medicine.disease_cause ,Liver disease ,Japan ,Virology ,Prevalence ,Humans ,Medicine ,Aged ,Aged, 80 and over ,Human T-lymphotropic virus 1 ,biology ,business.industry ,Gene Products, env ,Hepatitis C ,Middle Aged ,medicine.disease ,biology.organism_classification ,HTLV-I Infections ,HTLV-I Antibodies ,Infectious Diseases ,Hepatocellular carcinoma ,Immunology ,Female ,Parasitology ,HTLV-I Antigens ,business - Abstract
Human T-lymphotropic virus type 1 (HTLV-1) infection is known to affect hepatitis C virus (HCV) clearance and to accelerate the development of hepatocellular carcinoma in HCV-infected patients. In this study, we found the prevalence and titer of an antibody recognizing the central region of the HTLV-1 Gp46 protein to be associated with the severity of chronic liver disease. The antibody prevalence was significantly correlated with the stage of chronic liver disease (P < 0.0001): 3 (14.3%) of 21 patients with minimal-mild chronic hepatitis, 12 (24%) of 50 with moderate-severe chronic hepatitis, 7 (87.5%) of 8 with liver cirrhosis, and 13 (100%) of 13 with hepatocellular carcinoma. These results indicate that the antibody may be a useful marker of the deterioration of liver disease in patients co-infected with HCV and HTLV-1. This antibody may be useful for the diagnosis of liver diseases and the development of more effective treatments.
- Published
- 2007